Your browser doesn't support javascript.
loading
Systems Biology Methods Applied to Blood and Tissue for a Comprehensive Analysis of Immune Response to Hepatitis B Vaccine in Adults.
Ben-Othman, Rym; Cai, Bing; Liu, Aaron C; Varankovich, Natallia; He, Daniel; Blimkie, Travis M; Lee, Amy H; Gill, Erin E; Novotny, Mark; Aevermann, Brian; Drissler, Sibyl; Shannon, Casey P; McCann, Sarah; Marty, Kim; Bjornson, Gordean; Edgar, Rachel D; Lin, David Tse Shen; Gladish, Nicole; Maclsaac, Julia; Amenyogbe, Nelly; Chan, Queenie; Llibre, Alba; Collin, Joyce; Landais, Elise; Le, Khoa; Reiss, Samantha M; Koff, Wayne C; Havenar-Daughton, Colin; Heran, Manraj; Sangha, Bippan; Walt, David; Krajden, Mel; Crotty, Shane; Sok, Devin; Briney, Bryan; Burton, Dennis R; Duffy, Darragh; Foster, Leonard J; Mohn, William W; Kobor, Michael S; Tebbutt, Scott J; Brinkman, Ryan R; Scheuermann, Richard H; Hancock, Robert E W; Kollmann, Tobias R; Sadarangani, Manish.
Afiliación
  • Ben-Othman R; Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
  • Cai B; Telethon Kids Institute, University of Western Australia, Nedlands, WA, Australia.
  • Liu AC; Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
  • Varankovich N; Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
  • He D; Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
  • Blimkie TM; Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
  • Lee AH; Centre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, BC, Canada.
  • Gill EE; Simon Fraser University, Burnaby, BC, Canada.
  • Novotny M; Centre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, BC, Canada.
  • Aevermann B; Department of Informatics, J. Craig Venter Institute (La Jolla), La Jolla, CA, United States.
  • Drissler S; Department of Informatics, J. Craig Venter Institute (La Jolla), La Jolla, CA, United States.
  • Shannon CP; Terry Fox Laboratory, Vancouver, BC, Canada.
  • McCann S; Prevention of Organ Failure (PROOF) Centre of Excellence and Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada.
  • Marty K; Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
  • Bjornson G; Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
  • Edgar RD; Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
  • Lin DTS; Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
  • Gladish N; Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
  • Maclsaac J; Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
  • Amenyogbe N; Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
  • Chan Q; Telethon Kids Institute, University of Western Australia, Nedlands, WA, Australia.
  • Llibre A; Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Collin J; Translational Immunology Lab, Institut Pasteur, Paris, France.
  • Landais E; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States.
  • Le K; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States.
  • Reiss SM; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, United States.
  • Koff WC; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States.
  • Havenar-Daughton C; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, United States.
  • Heran M; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, United States.
  • Sangha B; Human Vaccines Project, New York, NY, United States.
  • Walt D; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, United States.
  • Krajden M; Department of Radiology, BC Children's Hospital, Vancouver, BC, Canada.
  • Crotty S; Department of Radiology, BC Children's Hospital, Vancouver, BC, Canada.
  • Sok D; Wyss Institute at Harvard University, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
  • Briney B; British Columbia Centre for Disease Control, Vancouver, BC, Canada.
  • Burton DR; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, United States.
  • Duffy D; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States.
  • Foster LJ; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, United States.
  • Mohn WW; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States.
  • Kobor MS; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States.
  • Tebbutt SJ; Translational Immunology Lab, Institut Pasteur, Paris, France.
  • Brinkman RR; Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Scheuermann RH; Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada.
  • Hancock REW; Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
  • Kollmann TR; Prevention of Organ Failure (PROOF) Centre of Excellence and Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada.
  • Sadarangani M; Department of Medicine, Division of Respiratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Front Immunol ; 11: 580373, 2020.
Article en En | MEDLINE | ID: mdl-33250895
Conventional vaccine design has been based on trial-and-error approaches, which have been generally successful. However, there have been some major failures in vaccine development and we still do not have highly effective licensed vaccines for tuberculosis, HIV, respiratory syncytial virus, and other major infections of global significance. Approaches at rational vaccine design have been limited by our understanding of the immune response to vaccination at the molecular level. Tools now exist to undertake in-depth analysis using systems biology approaches, but to be fully realized, studies are required in humans with intensive blood and tissue sampling. Methods that support this intensive sampling need to be developed and validated as feasible. To this end, we describe here a detailed approach that was applied in a study of 15 healthy adults, who were immunized with hepatitis B vaccine. Sampling included ~350 mL of blood, 12 microbiome samples, and lymph node fine needle aspirates obtained over a ~7-month period, enabling comprehensive analysis of the immune response at the molecular level, including single cell and tissue sample analysis. Samples were collected for analysis of immune phenotyping, whole blood and single cell gene expression, proteomics, lipidomics, epigenetics, whole blood response to key immune stimuli, cytokine responses, in vitro T cell responses, antibody repertoire analysis and the microbiome. Data integration was undertaken using different approaches-NetworkAnalyst and DIABLO. Our results demonstrate that such intensive sampling studies are feasible in healthy adults, and data integration tools exist to analyze the vast amount of data generated from a multi-omics systems biology approach. This will provide the basis for a better understanding of vaccine-induced immunity and accelerate future rational vaccine design.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Monitorización Inmunológica / Virus de la Hepatitis B / Vacunación / Vacunas contra Hepatitis B / Hepatitis B Tipo de estudio: Observational_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Front Immunol Año: 2020 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Monitorización Inmunológica / Virus de la Hepatitis B / Vacunación / Vacunas contra Hepatitis B / Hepatitis B Tipo de estudio: Observational_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Front Immunol Año: 2020 Tipo del documento: Article País de afiliación: Canadá